Myriad Genetics Ditches Medicare Overbilling Stock-Drop Suit
Myriad Genetics Inc. and its directors on Monday shook a proposed securities class action alleging a fraudulent billing of Medicare after a Utah federal judge ruled the suing investor failed to plead that the...To view the full article, register now.
Already a subscriber? Click here to view full article